Our Therapeutic Candidates
Trellis has derived five human monoclonal antibody (mAbs) therapeutics against bacterial, viral and cancer indications.
In vivo and in vitro experimental data show our antibodies possess superior binding affinity, broad-spectrum capabilities, and efficacy compared to alternative therapies
